Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > ARCHIVE
ARCHIVE
- Evidence-Based Treatment for Ischemic Heart Disease Needed
March 26, 2001
- Freund Creates New Company to Contract Manufacture Investigational New Drugs in US
March 26, 2001
- Company Reform Is Half-way Point to Top of Mountain: Takeda
March 26, 2001
- Fibrate Drugs Effective against Hypertriglyceridemia
March 26, 2001
- Clinical Trials Must Be Promoted from the Patients' Viewpoint: Prof. Nakano
March 26, 2001
- Seiwa Sangyo Introduces New System to Cut Costs
March 26, 2001
- WORLD NEWS IN BRIEF
March 26, 2001
- Introduction of CRC Certification System Being Considered
March 26, 2001
- Chuikyo Subcommittee to Form Consensus on Drug Prices by Autumn
March 26, 2001
- Mucosal Influenza Vaccine More Effective than Conventional Vaccines
March 26, 2001
- Mochida to Restructure Its Production System
March 26, 2001
- Chuikyo Subcommittee Starts Discussions for Next Revision of Medical Fees
March 26, 2001
- Draft Guidelines on Genetic Testing Compiled by Eight Societies
March 26, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF
March 26, 2001
- 850 Questions Received Regarding Evidence for Off-label Use of Drugs
March 26, 2001
- Gene Therapy for Buerger's Disease to Be Approved Shortly
March 26, 2001
- Applications Aimed at Preventing Accidents to Be Approved Quickly
March 26, 2001
- DIAGNOSTIC NEWS IN BRIEF
March 26, 2001
- LDP Convention Calls For Radical Reform in 2002
March 26, 2001
- MEDICAL DEVICE NEWS IN BRIEF
March 26, 2001
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…